Evolut™ PRO+

EXPECT MORE



Evolut™ PRO+
Transcatheter Aortic Valve System

Medtronic
Further, Together

THE EVOLUT™ PRO+ TAVI SYSTEM **ADVANTAGE**

From a design built on a proven platform[1], the EVOLUT™ PRO+ system provides the performance and outcomes you need to help patients live life to the fullest.



HEMODYNAMIC **PERFORMANCE**

for exceptional patient outcomes[2]

ADVANCED **SEALING**

for all valve sizes and across the broadest self-expanding annular range[†]

[†]Broadest annulus range based on CT derived diameters for self-expanding valves

LOW DELIVERY **PROFILE**

for access down to 5.0 mm vessels with the 23-29 mm valves

ACTOR PORTRAYAL

EVOLUT™ IS DESIGNED **TO DELIVER**

PERFORMANCE

The Evolut™ TAV's supra-annular, self-expanding valve design delivers exceptional hemodynamics and is the only TAVI device to demonstrate hemodynamic superiority in a low-risk clinical trial vs. SAVR.[2]

SUPERIOR
EOAs at 1 year

Evolut™ TAVI
2.3 cm²
VS.
SAVR 2.0 cm²

15%

LARGER EOAs

SUPERIOR
Gradients at 1 year

Evolut™ TAVI
8.2 mm Hg
VS.
SAVR 11.6 mm Hg

23%

LOWER GRADIENTS

Valves used in the Evolut™ Low Risk Trial included CoreValve™, Evolut™ R, and Evolut™ PRO valves.

Evolut™ TAVI has demonstrated large effective orifice areas (EOAs), thereby:

- **Lowering risk of severe patient-prosthesis mismatch (PPM)** and subsequently reducing risk of mortality and heart failure rehospitalizations[3]
- **Promoting increased blood flow** and minimizing PPM, allowing patients to maintain a higher exercise capacity, helping them return to an active life[4,5]
- **Suggesting a durable platform** given Evolut™ TAVI is built on the CoreValve™ supra-annular, self-expanding platform, which has consistently sustained large EOAs and low mean gradients over time[6]

ACTOR PORTRAYAL

LEADERSHIP IN **VALVE DESIGN**

Advanced Sealing across the Platform

The external tissue wrap on the Evolut™ PRO valves has shown excellent PVL performance.[7] With the addition of the wrap to the 34 mm PRO+ valve, similar results can be expected — offering advanced sealing across the platform.

Total Aortic Regurgitation

Real-world commercial experience from the STS/ACC TVT Registry™* demonstrates excellent PVL performance.

The views or opinions presented in this document are solely those of Medtronic and do not represent those of the American College of Cardiology, The Society of Thoracic Surgeons, or the STS/ACC TVT Registry™.

Total Aortic Regurgitation at 30 Days[7]



Evolut™ PRO
N = 1,444

ACTOR PORTRAYAL

TREAT MORE **PATIENTS**

Broadening Access with an Expanded Platform and Expanded Indication

- With a reduced delivery profile for 23-29 mm valves, the Evolut™ PRO+ System is indicated to treat patients with vessels as small as 5.0 mm
- With the ability to treat the broadest annulus range† of any commercially available self-expanding TAVI system, Evolut™ PRO+ valves can treat annulus ranges from 18 mm to 30 mm
- The Evolut™ PRO+ system is approved for all symptomatic severe aortic stenosis patients over ≥ 70 years of age or with a LVEF > 30%

† Broadest annulus range based on CT derived diameters for self-expanding valves

EVOLUT™ PRO+ SYSTEM

The Evolut™ PRO+ System treats the widest annulus range of any commercially available self-expanding TAVI system.



References
1. Data on file (>20 randomized controlled trials with over 20000 patients enrolled).
2. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. *N Engl J Med*. May 2, 2019;380(18):1706-1715.
3. Herrmann HC, Daneshvar SA, Fonarow GC, et al. Prosthesis-Patient Mismatch in 62,125 Patients Following Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry. *J Am Coll Cardiol*. December 4, 2018;72(22):2701-2711.
4. Bleiziffer S, Eichinger WB, Hettich I, et al. Impact of patient-prosthesis mismatch on exercise capacity in patients after bioprosthetic aortic valve replacement. *Heart*. May 2008;94(5):637-641.
5. Van Slooten YJ, van Melle JP, Freling HG, et al. Aortic valve prosthesis-patient mismatch and exercise capacity in adult patients with congenital heart disease. *Heart*. January 2016;102(2):107-113.
6. Gleason TG, Reardon MJ, Popma JJ, et al. 5-year Outcomes from the Randomized CoreValve US Pivotal High Risk Trial: Final Results. *J Am Coll Cardiol*. September 2018;72(13 Suppl).
7. Forrest JK, Williams MR, Popma JJ, et al. 30-Day Outcomes Following Transcatheter Aortic Valve Replacement With the Evolut PRO Valve in Commercial Use: A Report from the STS/ACC TVT Registry™. Presented at TCT 2018; San Diego, CA.

See the CoreValve™ Evolut™ R, the CoreValve™ Evolut™ PRO and the Evolut™ PRO+ device manuals for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events.
For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.

For applicable products, consult instructions for use on manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

The commercial name of the Evolut™ R device is Medtronic CoreValve™ Evolut™ R System, the commercial name of the Evolut™ PRO device is Medtronic CoreValve™ Evolut™ PRO System, and the commercial name of the Evolut™ PRO+ device is Medtronic Evolut™ PRO+ System.

Medtronic

Europe
Medtronic International Trading Sàrl.
Route du Molliau 31
Case postale
CH-1131 Tolochenaz
Tel: +41 (0)21 802 70 00
Fax: +41 (0)21 802 79 00

medtronic.eu